Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

Cancer research - 15 Apr 2008

Swisher Elizabeth M, Sakai Wataru, Karlan Beth Y, Wurz Kaitlyn, Urban Nicole, Taniguchi Toshiyasu

Abstract excerpt

Although ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance. Previously, we showed that acquired resistance to cisplatin in BRCA2-mutated tumors can be mediated by secondary intragenic mutations in BRCA2 that restore the wild-type BRCA2 reading frame. Here, we show that secondary mutations of BRCA1 also occur in BRCA1-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to DNA, Neoplasm

Share to Drug Resistance, Neoplasm

Share to Immunohistochemistry

Share to Ovarian Neoplasms

Share to Platinum Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 18413725
DOI: 10.1158/0008-5472.CAN-08-0088
PMCID: PMC2674369

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.PMID 18413725Read ↗

Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.Semantic proximity Read ↗

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.Semantic proximity Read ↗

Secondary Somatic Mutations Restoring<i>BRCA1/2</i>Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasSemantic proximity Read ↗

Secondary mutations of BRCA1/2 and drug resistance.Semantic proximity Read ↗

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.Semantic proximity Read ↗

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.Semantic proximity Read ↗

RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.Semantic proximity Read ↗

BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.Semantic proximity Read ↗

Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.Semantic proximity Read ↗

The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.Semantic proximity Read ↗

Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancerSemantic proximity Read ↗

Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.